Movement Disorder News and Research

Latest Movement Disorder News and Research

Scientists identify new strategy for treating movement disorders

Scientists at the Gladstone Institute of Neurological Disease and Stanford University have shown how key circuits in the brain control movement. The research, published in the journal Nature not only establishes the function of these circuits, but offers promise for treating movement related disorders, such as Parkinson's disease.

8 Jul 2010

Experts to discuss latest advancements in neurological disorders at Neurorehabilitation Symposium

Scientists and engineers from around the globe will gather in August to share new information regarding neurorehabilitation advances for people with neurological movement disorders, including spinal cord and brain injures.

2 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

In 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the structure of an ion channel his lab had been studying for five years.

24 Jun 2010

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.

23 Jun 2010

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

18 Jun 2010

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

An assessment of patients with adult Tourette syndrome (TS) to identify clinical factors that contribute to psychosocial and occupational disabilities resulting from the vocal or motor tics that define TS found that anxiety/panic disorder may be the most disabling psychiatric condition associated with the disorder.

18 Jun 2010

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea Therapeutics International, Ltd. announced that data from its pivotal studies of Northera™ (droxidopa) in symptomatic neurogenic orthostatic hypotension was presented during a poster session and featured in a symposium highlighting the role of norepinephrine (NE) deficiency in Parkinson's disease at the 14th International Congress on Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

17 Jun 2010

Prevalence of GID in PD patients has impact on clinical and societal outcomes: Study

New data from a retrospective cohort study showed that up to three quarters of patients with Parkinson's disease developed gastrointestinal disorders that can have a substantial adverse effect on major PD-related clinical and health economic outcomes. These data were presented at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010).

16 Jun 2010

Study confirms Azilect as a selective MAO-B inhibitor

Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.

4 Jun 2010

U-M researchers one step closer to discovering why certain diseases affect specific organs

Why do some diseases affect only specific organs, leaving others invulnerable? Researchers from the University of Michigan have found neural tissue contains imbalanced levels of proteins, which may explain the brain's susceptibility to a debilitating childhood movement disorder.

3 Jun 2010

Research explains brain's susceptibility to dystonia

3 Jun 2010

DBS procedure effective for treating Parkinson's disease

Studies have shown that a "brain pacemaker" called deep brain stimulation (DBS) is an effective treatment for Parkinson's disease.

3 Jun 2010

Researchers use CASL MRI technique to map cerebral blood flow patterns in schizophrenic patients

Researchers in Germany have used a magnetic resonance imaging technique called continuous arterial spin labeling to map cerebral blood flow patterns in schizophrenic patients quickly and without using radiation or contrast agents. Their findings appear in the online edition and July printed issue of the journal Radiology.

26 May 2010

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 30, 2010.

25 May 2010

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

TPP Global Development, an innovative drug development company, announced today it has raised £9.6m which will be used to execute the Company's strategy to develop early-stage pre-clinical drug candidates.

19 May 2010

Being physical and mental activity delays onset of Huntington’s disease: Research

Melbourne researchers report in a study that regular physical and mental activities can delay the onset of the dreaded genetic Huntington's disease. This disease is hereditary and it goes on to destroy the brain and nerve cells leading to loss of all or most faculties. It affects one in 10,000 people between ages 30 and 50 and there is no cure. Since it is passed on to the children at least 50% of the time the decision to have children also becomes an agonizing one for many sufferers.

13 May 2010

Imperial College London and McGill University expand scientific collaboration

Neurological research and clinical care received a significant boost today as Imperial College London and McGill University of Montreal entered an agreement enabling them to work more closely together in this field.

11 May 2010

Tel Aviv University researcher pioneers 3-D occupational therapy for children with disabilities

It was her love of ballet that led her to work with children who have motor disabilities. The retired dancer, now an occupational therapist, is pioneering a new "virtual" method to analyze movement patterns in children ― and more effectively treat those with debilitating motor disorders.

28 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Movement Disorder News and Research

Latest Movement Disorder News and Research

Scientists identify new strategy for treating movement disorders

Experts to discuss latest advancements in neurological disorders at Neurorehabilitation Symposium

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Prevalence of GID in PD patients has impact on clinical and societal outcomes: Study

Study confirms Azilect as a selective MAO-B inhibitor

U-M researchers one step closer to discovering why certain diseases affect specific organs

Research explains brain's susceptibility to dystonia

DBS procedure effective for treating Parkinson's disease

Researchers use CASL MRI technique to map cerebral blood flow patterns in schizophrenic patients

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

Being physical and mental activity delays onset of Huntington’s disease: Research

Imperial College London and McGill University expand scientific collaboration

Tel Aviv University researcher pioneers 3-D occupational therapy for children with disabilities

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Movement Disorder News and Research

Latest Movement Disorder News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in